3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Exclusion Criteria

• •1. Known allergy to any of the active ingredients or excipients of the study drug, or have a history of allergy to other opioids or non-steroidal anti-inflammatory drugs (NSAIDs) and their related ingredients.
• •2. Have a persistent pain resulted from other medical conditions or unknown causes.
• •3. Subjects presenting with emergency symptoms such as intestinal obstruction/perforation, spinal cord compression, epidural metastasis, or fracture.
• •4. Subjects with known active/symptomatic central nervous system metastasis and/or cancerous meningitis.
• •5. Subjects plan to be treated with \>10 mg/ day of prednisone or equivalent systemic corticosteroid during the study period.
• •6. Have a history of gastrointestinal bleeding or perforation.
• •7. Have a positive result of fecal occult blood test during screening period.
• •8. Have a history of serious cardiovascular diseases.
• •9. Have a history of an acute ischemic or hemorrhagic stroke within 6 months prior to screening.
• •10. Have a history of significant psychiatric disorders, such as schizophrenia and depression.
• •11. Subjects plan to receive radiotherapy, surgery, or a new regimen of systemic antitumor agents during the study treatment period (D1-D15).
• •12. Subjects have a history of alcohol abuse or drug abuse including opioids.
• •13. Subjects have significant opioid contraindications.
• •14. Pregnant or lactating women.
• •15. Subjects with other diseases that affect the oral administration or absorption of drugs.
• •16. Subjects are currently participating in another clinical study.
• •17. Other conditions deemed by the investigator to be inappropriate for participation in this study, such as poor compliance.